David Kabakoff, Ph.D.   |   Chairman

David joined Sofinnova as an Executive Partner in 2007. He represents Sofinnova as the Chairman of NextCure, and as Director of Antiva Biosciences, Dauntless Pharmaceuticals, BioClin Therapeutics, and Principia. He also serves as Chairman of Lineagen and as a Director of bioTheranostics and Castle BioSciences. Previously he served as the Chairman of both Trius Therapeutics and Amplimmune (now MedImmune/AstraZeneca), and as a Director of InterMune and Allylix.

Prior to Sofinnova, David spent almost 30 years in industry leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields. David co-founded Salmedix, a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer. In 2005, he negotiated the acquisition of Salmedix by Cephalon. David also held the positions of Executive Vice President of Dura and President and Chief Executive Officer of Spiros while at Dura Pharmaceuticals, a specialty respiratory pharmaceutical and pulmonary drug delivery company. Earlier, David was also employed as Chief Executive Officer of Corvas International and held senior executive positions with Hybritech. David received his Ph.D. from Yale University and his B.A. from Case Western Reserve University.

• David Kabakoff, Ph.D.
Chairman
• Elaine V. Jones, Ph.D.
Director
• Chau Q. Khuong
Director
• Judith J. Li
Director
• Tim Shannon, M.D.
Director